PlatformQ Health Education has delivered trustworthy, actionable, educating hundreds of thousands of HCPs. Our team of industry-leading experts create education that meets the needs of today’s clinician – from addressing knowledge gaps and developing activities to address them, to delivering engaging activities to the right learner, to measuring and reporting on the impact of that education.
Starting today, across our network, activities will air from multiple educational series. Compared to a single session, educational series provide greater educational value to participating clinicians, by providing deeper insights and more opportunity to address and reinforce practice and/or a patient outcome gaps. The evidence suggests that “multiple exposures produced better knowledge gains than a single exposure to content” (Effectiveness of Continuing Medical Education, The Johns Hopkins University, Evidence-based Practice Center, Baltimore, MD, 2007), and online serial CME activities are the perfect platforms to address these learning needs. The same study pointed out difference in teaching effectiveness, with print media being least effective in inducing knowledge and competency changes, and interactive, multimedia activities most effective.
PlatformQ Health has and will continue to collaborate with leading member organizations and patient advocacy group partners to create educational CME series that are live, sequential, interactive, and available for HCPs to watch and re-watch on-demand.
Upcoming Series Education
Series Education about Multiple Sclerosis
NeuroSeriesLive, PlatformQ Health’s neurology home for HCPs, is continuing a 3-part series called, “Grasping Precision Medicine in Multiple Sclerosis: 2020 Education Series for Beginners, Mid-Level, and Experienced Medicine in Multiple Sclerosis.” The activities are produced in partnership with The Consortium of Multiple Sclerosis Centers. Session 1 of the series, “Precision Medicine with Polypharmacy in Multiple Sclerosis: What does it mean in practice?” is currently available on-demand on NeuroSeriesLive.
Session 2 and 3 will air live online September 14th starting at 1pm with “Multiple Sclerosis Research to Practice I: Neuropathology and Biomarkers.” This activity will review the most up-to-date evidence with biomarkers in MS and their current and future role in diagnosis and guiding treatment decisions. At 2pm, “Multiple Sclerosis Research to Practice II: High-Efficacy DMTs” be live, and will feature expert panelists, Dr. Ellen Mowry, Professor of Neurology and Epidemiology at Johns Hopkins University and Dr. Daniel Ontaneda, Associate Professor of Neurology at Cleveland Clinic Lerner College of Medicine of Case Western Reserve University. They will engage in a lively discussion regarding long-term outcomes of treatment with high-efficacy DMTs, and data released during 2020 medical and research conferences from registries and clinical trials that are identifying and addressing gaps in knowledge regarding treatment decisions in MS.
National Conferences CME Series on Atopic Dermatitis
In August, PlatformQ and the Asthma and Allergy Foundation of America (AAFA) partnered to better equip health care providers in diagnosing, treating, and communicating with patients. As part of this initiative is the upcoming 2-part virtual activity about atopic dermatitis on ImmunologyLive for allergists, dermatologists, primary care physicians, pediatricians, advanced practitioners, pharmacists, and nurses. Session 1, “Aligning Treatment with Disease Burden and Severity to Optimize Success,” airs live on September 17th at 2PM ET, and is followed up Session 2, “Atopic Dermatitis: A Clear Roadmap to Treatment Success” at 3PM ET.
This program’s expert panel will include Dr. Peter Lio, Clinical Assistant Professor of Dermatology & Pediatrics at Northwestern University Feinberg School of Medicine, Paul P. Doghramji, MD, FAAFP, Medical Director of Health Services at Ursinus College, and Kafi Brown of the Asthma & Allergy Foundation of America.
The overarching goals of this series are to enhance clinicians’ confidence in:
- Combining information gathered from clinical examination and evaluation of disease burden to confirm a diagnosis and determine disease severity in children, adolescents, and adults with AD
- Describing how targeted treatment options overcome the limitations of traditional topical and systemic treatments and result in improved symptom control and QoL outcomes for people with AD and their caregivers
- Integrating components of shared decision-making that includes ongoing assessment of QoL, symptoms and disease severity for monitoring of progress with prompt adjustment of treatment to achieve patient’ s preferred goals
Continuing Medical Education for Breast Cancer Management
On September 21st, PlatformQ Health will launch a series on breast cancer management on its oncology learning channel, OMedLive featuring Dr. Adam Brufsky, Professor of Medicine at the University of Pittsburgh School of Medicine and Dr. Stephen Liu, Associate Professor of Medicine and Director of Thoracic Oncology & Developmental Therapeutics at the Lombardi Comprehensive Cancer Center of Georgetown University. During this two-part series, the faculty will take learners on a journey that explores how to effectively optimize the use of HER-directed agents and their emerging clinical applications.
Session 1, “Targeting HER2/HER3 in HER-Expressing Tumor Types” will be live at 1pm. HCPs will hear from experts on the potential heterogeneity of HER2 status, the relationship between HER2 and HER3, and the molecular mechanisms that give rise to HER2 treatment resistance.
“HER Directed Cancer Therapy” will be live immediately following at 2pm, with a review of the most recent clinical-trial data on recently approved and investigational HER2-directed agents. A patient case will help guide the discussion of efficacy and safety data, treatment selection, and side-effect management.
Have any questions about multi-session educational CME series or want to learn more about partnering with us to educate HCPs online? Email us at email@example.com.